Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Pharmaceutical interventions in the management of tuberculosis in a pneumophtisiology department, Ivory Coast

Authors Abrogoua DP, Kamenan BAT, Ahui BJM, Doffou E

Received 29 July 2016

Accepted for publication 9 October 2016

Published 22 November 2016 Volume 2016:12 Pages 1749—1756

DOI https://doi.org/10.2147/TCRM.S118442

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Danho Pascal Abrogoua,1 Boua Alexis Thierry Kamenan,1 Brou Jean Marcel Ahui,2 Elisée Doffou3

1Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, 2Department of Pneumophtisiology, Teaching Hospital of Cocody, 3Department of Pharmacy, Teaching Hospital of Yopougon, Abidjan, Cote d’Ivoire


Objectives: This study aims to analyze the profile and relevance of pharmaceutical interventions (PIs) in the management of tuberculosis (TB) at inpatient settings.
Patients and methods: Cross-sectional descriptive study conducted from March to December 2014 within the inpatient unit of pneumophtisiology department, Ivory Coast. Information collected was based on the classification of drug-related problems (DRPs) and PIs outlined by the French Society of Clinical Pharmacy. A score was assigned to each PI according to the importance of the potential clinical impact. This score was correlated with the severity of clinical consequences avoided by the intervention. The listing of interventions was made by pneumophtisiology specialists. The score assigned to each intervention ranged from 0 (without clinical impact) to 3 (vital clinical impact). The acceptance rate of interventions by physicians was evaluated.
Results: Of 130 patients, 28.5% received PIs. The main reasons for interventions were drug–drug interactions (26.4%), noncompliance with recommendations (24.5%), and adverse effects (24.5%). Antituberculosis drugs were involved in 40.3% of DRPs. Interventions were predominantly proposals for monitoring treatment effectiveness and safety parameters (52.7%) followed by proposals of therapeutic choice (28.1%). All interventions were accepted by the physicians. Most interventions (59.6%) were listed as interventions with significant clinical impact.
Conclusion: The presence of a pharmacist at inpatient setting has contributed to the prevention and resolution of problems related to the pharmacotherapeutic management of TB. Pharmacists can position themselves as major players in the therapeutic management of TB inpatient in resource-limited setting.

Keywords: tuberculosis, drug-related problem, pharmaceutical intervention, relevance, clinical impact, Ivory Coast

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings

Abrogoua DP, Kablan BJ, Kamenan BAT, Aulagner G, N'Guessan K, Zohoré C

Patient Preference and Adherence 2012, 6:227-237

Published Date: 23 March 2012